Oscar Health (NYSE: OSCR) to repeat 2025 guidance at Wells Fargo event

Rhea-AI Filing Summary

Oscar Health, Inc. plans to take part in the 2025 Wells Fargo Healthcare Conference on September 3, 2025, where it will reaffirm the updated full-year 2025 guidance it previously shared in its July 22, 2025 preliminary second-quarter results press release. This means the company is publicly standing by its current 2025 financial outlook when speaking with investors at the event.

The company also reminds readers that any statements about expected financial performance are forward-looking and subject to risks and uncertainties described in its recent annual and quarterly reports filed with the SEC.

8-K Event Classification

Item 7.01 — Regulation FD Disclosure

1 item

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Understanding 8-K Material Events →

false 0001568651 0001568651 2025-09-03 2025-09-03

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): September 3, 2025

Oscar Health, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware		001-40154		46-1315570
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

75 Varick Street, 5th Floor

New York, New York 10013

(Address of Principal Executive Offices) (Zip Code)

(646) 403-3677

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A Common Stock, $0.00001 par value per share		OSCR		New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

Oscar Health, Inc. (the “Company”) will participate in the 2025 Wells Fargo Healthcare Conference (the “Conference”) on September 3, 2025. At the Conference, the Company will reaffirm the updated full year 2025 guidance that it provided in its preliminary financial results press release for the second quarter of 2025, dated July 22, 2025.

This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in any such filing.

Cautionary Note Regarding Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained herein are forward- looking statements. These statements include, but are not limited to, statements about our expected financial performance and upcoming events and presentations. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions, and uncertainties that are difficult to predict and generally beyond our control. Although management believes that the expectations reflected in these forward-looking statements are reasonable as of the date made, there are or will be important factors that could cause our actual results to differ materially from those indicated in these forward-looking statements, including, but not limited to, the factors set forth under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”), our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, and our other filings with the SEC. You are cautioned not to place undue reliance on any forward-looking statements made herein. Any forward-looking statement speaks only as of the date as of which it is made, and, except as otherwise required by law, we do not undertake any obligation to publicly update or review any forward- looking statement, whether as a result of new information, future developments or otherwise. New factors emerge from time to time, and it is not possible for us to predict which will arise.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Oscar Health, Inc.
Date: September 3, 2025				By:		/s/ R. Scott Blackley
						R. Scott Blackley
						Chief Financial Officer

FAQ

What did Oscar Health (OSCR) disclose in this 8-K filing?

Oscar Health disclosed that it will participate in the 2025 Wells Fargo Healthcare Conference on September 3, 2025 and will reaffirm its updated full-year 2025 guidance that was previously provided in a July 22, 2025 preliminary second-quarter results press release.

What guidance is Oscar Health (OSCR) reaffirming at the 2025 Wells Fargo Healthcare Conference?

The company is reaffirming its updated full year 2025 guidance, which it had already communicated in its preliminary financial results press release for the second quarter of 2025 dated July 22, 2025.

Does this Oscar Health (OSCR) 8-K include detailed financial figures for 2025 guidance?

No, this disclosure only states that Oscar Health will reaffirm the updated full-year 2025 guidance previously provided in the July 22, 2025 press release; specific figures are not repeated here.

Is the information in this Oscar Health (OSCR) 8-K considered filed or furnished?

The company states that this information is not deemed “filed” for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other Securities Act or Exchange Act filings unless specifically referenced.

What forward-looking statement cautions does Oscar Health (OSCR) provide?

Oscar Health notes that statements about expected financial performance and events are forward-looking, are not guarantees of future performance, and are subject to risks and uncertainties discussed under “Risk Factors” in its Form 10-K for the year ended December 31, 2024, its Form 10-Q for the quarter ended June 30, 2025, and other SEC filings.

Who signed this Oscar Health (OSCR) 8-K filing?

The report was signed on behalf of Oscar Health, Inc. by R. Scott Blackley, the company’s Chief Financial Officer, dated September 3, 2025.